HighVista Strategies’s Tyra Biosciences TYRA Stock Holding History

HighVista Strategies’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.03M	Buy	131,304 +96,218	+274%	+$3.11M	1.39%	13
2025 Q4	$922K	Sell	35,086 -30,726	-47%	-$564K	0.24%	116
2025 Q3	$921K	Buy	65,812 +40,850	+164%	+$466K	0.23%	124
2025 Q2	$239K	Buy	24,962 +1,021	+4%	+$9.7K	0.09%	143
2025 Q1	$223K	Hold	23,941	–	–	0.09%	145
2024 Q4	$333K	Buy	23,941 +7,863	+49%	+$143K	0.12%	136
2024 Q3	$378K	Hold	16,078	–	–	0.13%	141
2024 Q2	$257K	Buy	+16,078	New	+$277K	0.09%	136

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

HighVista Strategies's TYRA Position: Q1 2026 in Review

HighVista Strategies increased its Tyra Biosciences (TYRA) stake by 274% in Q1 2026, buying an estimated $3.11M and bringing the position to 131,304 shares worth $5.03M. The position accounts for 1.39% of the portfolio, ranked #13.

HighVista Strategies first reported a position in TYRA in Q2 2024 and has held it in 8 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

HighVista Strategies held 131,304 shares of Tyra Biosciences worth $5.03M as of Q1 2026.
HighVista Strategies bought 96,218 Tyra Biosciences shares in Q1 2026, an estimated $3.11M.
Tyra Biosciences made up 1.39% of HighVista Strategies's portfolio in Q1 2026, its #13 holding.
HighVista Strategies first reported a position in Tyra Biosciences in Q2 2024 and has held it in 8 quarters since.
164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.